NASDAQ: NAUT
Nautilus Biotechnology Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their NAUT stock forecasts and price targets.

Forecast return on equity

Is NAUT forecast to generate an efficient return?

Company
-38.93%
Industry
83.55%
Market
67.39%
NAUT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NAUT forecast to generate an efficient return on assets?

Company
-33.24%
Industry
22.55%
NAUT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NAUT earnings per share forecast

What is NAUT's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.56
Avg 2 year Forecast
-$0.64
Avg 3 year Forecast
-$0.60

NAUT revenue forecast

What is NAUT's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$200.0k
Avg 2 year Forecast
$3.9M
Avg 3 year Forecast
$18.1M

NAUT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NAUT$0.70N/AN/A
CHRS$0.76$4.03+428.22%Buy
MIST$1.65$7.50+354.55%Buy
BMEA$2.36$11.00+366.10%Strong Buy
IOBT$1.35$12.00+788.89%Buy

Nautilus Biotechnology Stock Forecast FAQ

What is NAUT's earnings growth forecast for 2025-2027?

(NASDAQ: NAUT) Nautilus Biotechnology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.71%.

Nautilus Biotechnology's earnings in 2025 is -$68,663,000.On average, 2 Wall Street analysts forecast NAUT's earnings for 2025 to be -$70,012,400, with the lowest NAUT earnings forecast at -$73,166,112, and the highest NAUT earnings forecast at -$66,858,689. On average, 2 Wall Street analysts forecast NAUT's earnings for 2026 to be -$80,735,020, with the lowest NAUT earnings forecast at -$84,519,474, and the highest NAUT earnings forecast at -$76,950,566.

In 2027, NAUT is forecast to generate -$75,689,081 in earnings, with the lowest earnings forecast at -$75,689,081 and the highest earnings forecast at -$75,689,081.

If you're new to stock investing, here's how to buy Nautilus Biotechnology stock.

What is NAUT's revenue growth forecast for 2025-2027?

(NASDAQ: NAUT) Nautilus Biotechnology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 130.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.

Nautilus Biotechnology's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast NAUT's revenue for 2025 to be $25,229,694, with the lowest NAUT revenue forecast at $25,229,694, and the highest NAUT revenue forecast at $25,229,694. On average, 2 Wall Street analysts forecast NAUT's revenue for 2026 to be $494,123,553, with the lowest NAUT revenue forecast at $92,719,125, and the highest NAUT revenue forecast at $895,654,130.

In 2027, NAUT is forecast to generate $2,285,557,961 in revenue, with the lowest revenue forecast at $2,285,557,961 and the highest revenue forecast at $2,285,557,961.

What is NAUT's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: NAUT) forecast ROA is -33.24%, which is lower than the forecast US Biotechnology industry average of 22.55%.

What is NAUT's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: NAUT) Nautilus Biotechnology's current Earnings Per Share (EPS) is -$0.54. On average, analysts forecast that NAUT's EPS will be -$0.56 for 2025, with the lowest EPS forecast at -$0.58, and the highest EPS forecast at -$0.53. On average, analysts forecast that NAUT's EPS will be -$0.64 for 2026, with the lowest EPS forecast at -$0.67, and the highest EPS forecast at -$0.61. In 2027, NAUT's EPS is forecast to hit -$0.60 (min: -$0.60, max: -$0.60).

What is NAUT's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: NAUT) forecast ROE is -38.93%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.